Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
A Phase 1 Study of H3B-6545 in Japanese Women With Estrogen Receptor-positive, HER2 Negative Breast Cancer
Sponsor: Eisai Co., Ltd.
A PHASE1 clinical study on Breast Neoplasms, this trial is completed. The trial is conducted by Eisai Co., Ltd. and has accumulated 15 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
15 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1
-
Feb 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
-
Dec 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 10 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
Oct 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE1
-
Jan 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — Feb 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Sep 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eisai Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .